Ocular Therapeutix (Ocular Therapeutix) Total Inventories

: $2.31 Mil (As of Dec. 2023)

View and export this data going back to 2014. Start your Free Trial

Ocular Therapeutix's total inventories for the quarter that ended in Dec. 2023 was $2.31 Mil. Ocular Therapeutix's average total inventories from the quarter that ended in Sep. 2023 to the quarter that ended in Dec. 2023 was $2.28 Mil.

In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. Ocular Therapeutix's Net-Net Working Capital per share for the quarter that ended in Dec. 2023 was $0.48.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory. Ocular Therapeutix's Days Inventory for the three months ended in Dec. 2023 was 150.17.

Inventory Turnover measures how fast the company turns over its inventory within a year. Ocular Therapeutix's Inventory Turnover for the quarter that ended in Dec. 2023 was 0.61.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Ocular Therapeutix's Inventory-to-Revenue for the quarter that ended in Dec. 2023 was 0.15.

Ocular Therapeutix Total Inventories Historical Data

The historical data trend for Ocular Therapeutix's Total Inventories can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ocular Therapeutix Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Inventories

Get a 7-Day Free Trial

0.95

1.20

1.25

1.97

2.31

Ocular Therapeutix Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Total Inventories	Get a 7-Day Free Trial															1.97	2.27	2.20	2.26	2.31

Ocular Therapeutix Total Inventories Calculation

Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.

Ocular Therapeutix (NAS:OCUL) Total Inventories Explanation

Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.

1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.

Ocular Therapeutix's Net-Net Working Capital Per Share for the quarter that ended in Dec. 2023 is

	Net-Net Working Capital Per Share (Q: Dec. 2023 )
=	(Cash And Cash Equivalents	+	0.75 * Accounts Receivable	+	0.5 * Total Inventories	-	Total Liabilities
-	Preferred Stock	-	Minority Interest)	/	Shares Outstanding (EOP)
=	(195.807	+	0.75 * 26.179	+	0.5 * 2.305	-	160.929
-	0	-	0)	/	114.963
=	0.48

2. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Ocular Therapeutix's Days Inventory for the three months ended in Dec. 2023 is calculated as:

Days Inventory	=	Average Total Inventories (Q: Dec. 2023 )	/	Cost of Goods Sold (Q: Dec. 2023 )	*	Days in Period
	=	2.281	/	1.386	*	365 / 4
	=	150.17

3. Inventory Turnover measures how fast the company turns over its inventory within a year.

Ocular Therapeutix's Inventory Turnover for the quarter that ended in Dec. 2023 is calculated as

Inventory Turnover	=	Cost of Goods Sold (Q: Dec. 2023 )	/	Average Total Inventories (Q: Dec. 2023 )
	=	1.386	/	2.281
	=	0.61

4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Ocular Therapeutix's Inventory to Revenue for the quarter that ended in Dec. 2023 is calculated as

Inventory-to-Revenue	=	Average Total Inventories (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	2.281	/	14.801
	=	0.15

Be Aware

Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.

When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.

Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.

Ocular Therapeutix Total Inventories Related Terms

Thank you for viewing the detailed overview of Ocular Therapeutix's Total Inventories provided by GuruFocus.com. Please click on the following links to see related term pages.

Ocular Therapeutix (Ocular Therapeutix) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ocular Therapeutix Inc (NAS:OCUL) » Definitions » Total Inventories

Comparable Companies

Traded in Other Exchanges

0OT:Germany 0OT:Germany

Address

24 Crosby Drive, Bedford, MA, USA, 01730

Website

https://www.ocutx.com

Ocular Therapeutix Inc is a biotechnology company that specializes in therapies for diseases and conditions of the eye. The company uses its proprietary hydrogel platform technology to deliver therapeutic agents to the eye. Its pipeline consists of eye medication that aims to overcome the limitations of current eye-drop-based therapies for ophthalmic diseases and conditions. Ocular Therapeutix aims to offer medication to replace the existing eye-drop therapy regimen, with the aim of lasting weeks or months with a one-time product application. Its pipeline product includes Dextenza, OTX-TIC, OTX-TKI, and OTX-IVT.

Executives

Summer Road Llc	10 percent owner	207 6TH STREET, WEST PALM BEACH FL 33401
Antony C. Mattessich	director	C/O OCULAR THERAPEUTIX, INC., 34 CROSBY DR., SUITE 105, BEDFORD MA 01730
Adrienne L Graves	director	125 STONE MOUNTAIN CIRCLE, NAPA CA 94558
Rabia Gurses Ozden	officer: Chief Medical Officer	C/O AKOUOS, INC., 645 SUMMER STREET SUITE 200, BOSTON MA 02210
Philip C. Strassburger	officer: General Counsel	24 CROSBY DRIVE, BEDFORD MA 01730
Donald Notman	officer: Chief Financial Officer	C/O OCULAR THERAPEUTIX, INC., 15 CROSBY DRIVE, BEDFORD MA 01730
Christopher G White	officer: Chief Business Officer	C/O AMAG PHARMACEUTICALS, INC., 1100 WINTER STREET, WALTHAM MA 02451
Jeffrey S. Heier	director	C/O OCULAR THERAPEUTIX, INC., 34 CROSBY DR., SUITE 105, BEDFORD MA 01730
Merilee Raines	director	IDEXX LABORATORIES, INC., ONE IDEXX DRIVE, WESTBROOK ME 04092
Lindstrom Richard L Md	director	2811 WESTWOOD PL, WAYZATA MN 55391
Opaleye Management Inc.	10 percent owner	ONE BOSTON PLACE, SUITE 2600, BOSTON MA 02108
Patricia Kitchen	officer: Chief Operations Officer	C/O OCULAR THERAPEUTIX, INC., 15 CROSBY DRIVE, BEDFORD MA 01730
Leslie J. Williams	director	C/O OCULAR THERAPEUTIX, INC., 15 CROSBY DRIVE, BEDFORD MA 01730
Seung Suh Hong	director	C/O OCULAR THERAPEUTIX, INC., 15 CROSBY DRIVE, BEDFORD MA 01730
Amarpreet Sawhney	director, 10 percent owner, officer: President and CEO	C/O OCULAR THERAPEUTIX, INC., 36 CROSBY DRIVE, SUITE 101, BEDFORD MA 01730